Teachers Retirement System of The State of Kentucky Acquires New Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Teachers Retirement System of The State of Kentucky purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 52,392 shares of the biotechnology company's stock, valued at approximately $1,047,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Calamos Advisors LLC lifted its holdings in ADMA Biologics by 8.3% in the 2nd quarter. Calamos Advisors LLC now owns 603,003 shares of the biotechnology company's stock worth $6,742,000 after purchasing an additional 46,405 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of ADMA Biologics by 6.9% during the second quarter. Bank of New York Mellon Corp now owns 766,544 shares of the biotechnology company's stock valued at $8,570,000 after buying an additional 49,631 shares during the last quarter. Viewpoint Capital Management LLC lifted its holdings in shares of ADMA Biologics by 32.4% in the second quarter. Viewpoint Capital Management LLC now owns 20,416 shares of the biotechnology company's stock worth $228,000 after buying an additional 5,000 shares in the last quarter. Rhumbline Advisers boosted its position in shares of ADMA Biologics by 5.4% during the second quarter. Rhumbline Advisers now owns 310,539 shares of the biotechnology company's stock worth $3,472,000 after acquiring an additional 15,844 shares during the last quarter. Finally, Victory Capital Management Inc. grew its stake in ADMA Biologics by 192.6% during the second quarter. Victory Capital Management Inc. now owns 84,046 shares of the biotechnology company's stock valued at $940,000 after acquiring an additional 55,322 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The shares were sold at an average price of $21.15, for a total transaction of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company's stock, valued at approximately $4,218,007.95. The trade was a 7.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 3.70% of the company's stock.

Analyst Ratings Changes

ADMA has been the topic of several research analyst reports. Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. Raymond James boosted their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research report on Friday, November 8th. Finally, HC Wainwright increased their price target on ADMA Biologics from $18.00 to $26.00 and gave the company a "buy" rating in a research note on Friday, November 8th.

ADMA Biologics Price Performance

ADMA stock traded up $0.20 during trading on Thursday, hitting $17.90. 2,074,536 shares of the company's stock traded hands, compared to its average volume of 3,559,266. ADMA Biologics, Inc. has a 52 week low of $4.06 and a 52 week high of $23.64. The stock has a market capitalization of $4.23 billion, a price-to-earnings ratio of 63.93 and a beta of 0.70. The business has a fifty day simple moving average of $18.90 and a 200 day simple moving average of $16.24. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analysts' expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the company earned $0.01 EPS. As a group, research analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.